UBS Group’s Mentari Therapeutics, Inc. Common Stock MTRI Stock Holding History
Bought
Maintained
Sold
Other funds holding MTRI
SFCM
UBS Group's MTRI Position: Q3 2026 in Review
UBS Group opened a new position in Mentari Therapeutics, Inc. Common Stock (MTRI) in Q3 2026: 319 shares worth $4.34K. The stake represents ﹤0.01% of the portfolio and ranks #9693 among its holdings. This is a return to the name: UBS Group previously reported a position in MTRI as recently as Q1 2026.
UBS Group first reported a position in MTRI in Q3 2021 and has held it in 11 quarters since. The position peaked at $50.3K in Q3 2024. 16 funds tracked by Wall St. Rank hold MTRI as of Q3 2026.
- UBS Group held 319 shares of Mentari Therapeutics, Inc. Common Stock worth $4.34K as of Q3 2026.
- Mentari Therapeutics, Inc. Common Stock was a new UBS Group position in Q3 2026.
- Mentari Therapeutics, Inc. Common Stock made up ﹤0.01% of UBS Group's portfolio in Q3 2026, its #9693 holding.
- UBS Group first reported a position in Mentari Therapeutics, Inc. Common Stock in Q3 2021 and has held it in 11 quarters since.
- UBS Group's Mentari Therapeutics, Inc. Common Stock position peaked at $50.3K in Q3 2024.
- 16 funds tracked by Wall St. Rank held Mentari Therapeutics, Inc. Common Stock as of Q3 2026.
Based on UBS Group's 13F filing for Q3 2026, filed 10 Nov 2026.